Research Analysts’ Recent Ratings Changes for Milestone Pharmaceuticals (MIST)

A number of research firms have changed their ratings and price targets for Milestone Pharmaceuticals (NASDAQ: MIST):

• 5/17/2026 – Milestone Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “strong sell”.
• 5/15/2026 – Milestone Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/14/2026 – Milestone Pharmaceuticals had its price target lowered by Wells Fargo & Company from $8.00 to $7.00. They now have an “overweight” rating on the stock.
• 5/9/2026 – Milestone Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/11/2026 – Milestone Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/10/2026 – Milestone Pharmaceuticals is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $6.00 price target on the stock.
• 4/9/2026 – Milestone Pharmaceuticals is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.
• 3/28/2026 – Milestone Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Activity

In other news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the sale, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is currently owned by insiders.

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.